

1Q25 RESULTS CALL PRESENTATION

7 MAY 2025

01 KEY DEVELOPMENTS IN 1Q25

02 MACROECONOMIC UPDATE | GEORGIA

1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX





KEY DEVELOPMENTS NAV per share (GEL) increased 11.2% in 1Q25, driven by continued growth in Lion Finance Group's (Bank of Georgia's) share price and the robust operating performance of the private portfolio companies



Outstanding quarterly results across our large private portfolio companies with 21.2% and 45.8% y-o-y increases in aggregated revenues and EBITDA in 1Q25, respectively, leading to a 25.2% y-o-y increase in net operating cash flow



3

NCC ratio increased by 0.7 ppts q-o-q to 13.5% as at 31-Mar-25, mainly reflecting the announcement of a US\$ 25 million increase to the buyback programme in March 2025

2.1 million shares repurchased since the beginning of 2025 (total bought back since demerger now 13.2 million shares (US\$ 164 million cost), representing 27.6%¹ of GCAP's peak issued share capital)

01	KEY DEVELOPMENTS IN 1Q2

NAV PER SHARE OVERVIEW AGGREGATED PORTFOLIO RESULTS OVERVIEW UPDATE ON DELEVERAGING NAV DISCOUNT DEVELOPMENT OVERVIEW

02 MACROECONOMIC UPDATE | GEORGIA

1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX



UPDATED NAV FORMAT



TO ENHANCE STAKEHOLDER VISIBILITY INTO GCAP'S PRIVATE **ASSETS AND STREAMLINE THE ASSESSMENT OF OUR PORTFOLIO** COMPANIES, WE HAVE IMPLEMENTED **UPDATES TO OUR DISCLOSURES**

- Following the update, our private portfolio is reported in two categories: 1) large portfolio companies and 2) emerging and other portfolio companies.
- The healthcare services business now combines the previously separately reported hospitals, clinics, and diagnostics businesses, reflecting their recently integrated management oversight.
- This update is expected to sharpen investors' focus on our three large-scale private portfolio businesses which, together with our listed and observable assets, account for more than 85% of the total portfolio value as of 31-Mar-25.

Portfolio breakdown before the update	Updated portfolio breakdown		
 Listed and observable portfolio companies Lion Finance Group (19.3% holding) Water utility (20% holding) 	 Listed and observable portfolio companies Lion Finance Group (19.3% holding) Water utility (20% holding) 	45% OF THE TOTAL PORTFOLIO VALUE	5%+
 Large portfolio companies Retail (pharmacy) Insurance (P&C and medical) Hospitals 	 Large portfolio companies Retail (pharmacy) Insurance (P&C and medical) Healthcare services 	41% OF THE TOTAL PORTFOLIO VALUE	
 Investment stage portfolio companies Renewable energy Education Clinics and diagnostics Other Auto service 	 Emerging and other portfolio companies Renewable energy Education Auto service Wine Real estate 	14% OF THE TOTAL PORTFOLIO VALUE	

• Wine


Real estate

NAV PER SHARE (GEL) MOVEMENT IN 1Q25




NAV PER SHARE (GEL) UP 11.2% Q-O-Q IN 1Q25

- The increase in NAV per share (GEL) in 1Q25 reflects continued growth in Lion Finance Group's share price and the robust operating performance of the private portfolio companies. The growth was supported by an accretive impact of share buybacks.
- As of 6-May-25, NAV per share was up by 20.9% from 31-Dec-24, reflecting growth in Lion Finance Group's share price, FX movements and GCAP's share buybacks.



STRONG NAV PER SHARE GROWTH





STRONG NAV PER SHARE (GEL) GROWTH WITH 15.1% CAGR SINCE DEC-18. IN US\$ AND GBP TERMS, NAV PER SHARE CAGR STANDS AT 14.5% AND 14.1%, RESPECTIVELY

5-YEAR NAV PER SHARE CAGR STANDS AT 28.7%, 33.2% AND 32.1% IN GEL, US\$ AND GBP TERMS, RESPECTIVELY

SHARE BUYBACK AND CANCELLATION PROGRAMME



13.2 MILLION SHARES (US\$ 164 MILLION IN VALUE) REPURCHASED AND CANCELLED SINCE DEMERGER IN 2018, REPRESENTING 27.6%¹ OF THE ISSUED SHARE CAPITAL AT ITS PEAK

DEVELOPMENT OF GCAP'S SHARE BUYBACK AND CANCELLATION PROGRAMMES

- > The gross number of issued shares, including those held by the management trust, is now below the share count at the time of the demerger Number of issued shares (million) 40.2 37.4 39.4 **47.9**² 47.1 44.8 43.2 39.5 \$164 \$128 13.2 11.1 \$80 \$61 7.4 \$43 5.8 \$36 \$36 \$18 3.5 2.7 2.7 2018 2019 2020 2021 2022 2023 2024 2025 to date Since demerger Value of shares repurchased (cummulative, US\$ million)
 - ----Number of shares repurchased (cummulative, million)


PROGRESS ON GEL 300 MILLION CAPITAL RETURN PROGRAMME

GEL MILLION



IN MAY-24, GCAP ANNOUNCED ITS **BOARD'S INTENTION TO MAKE AVAILABLE AT LEAST GEL 300 MILLION FOR SHARE BUYBACKS AND DIVIDENDS THROUGH THE END OF 2026**

- Total value of shares repurchased under the GEL 300 million capital return programme currently at GEL 216 million (US\$ 78 million).
- Of the remaining GEL 84 million (US\$ 31 million), GEL 35 million (US\$ 13 million) is currently being utilised under the ongoing US\$ 50 million share buyback programme.



01 KEY DEVELOPMENTS IN 1Q25

NAV PER SHARE OVERVIEW AGGREGATED PORTFOLIO RESULTS OVERVIEW UPDATE ON DELEVERAGING NAV DISCOUNT DEVELOPMENT OVERVIEW

02 MACROECONOMIC UPDATE | GEORGIA

1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP


06 ANNEX






AGGREGATED REVENUE DEVELOPMENT ACROSS PRIVATE PORTFOLIO





AGGREGATED EBITDA DEVELOPMENT ACROSS PRIVATE PORTFOLIO







AGGREGATED CASH BALANCE & NET OPERATING CASH FLOW DEVELOPMENT ACROSS PRIVATE PORTFOLIO







TOTAL AGGREGATED CASH BALANCE OF PRIVATE BUSINESSES (GEL MILLION)



01 KEY DEVELOPMENTS IN 1Q25

NAV PER SHARE OVERVIEW AGGREGATED PORTFOLIO RESULTS OVERVIEW UPDATE ON DELEVERAGING NAV DISCOUNT DEVELOPMENT OVERVIEW

- **02** MACROECONOMIC UPDATE | GEORGIA
- **1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW**
- **04** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX



NET CAPITAL COMMITMENT (NCC) OVERVIEW



NCC RATIO INCREASED BY 0.7 PPTS Q-O-Q AS OF 31-MAR-25

- A 0.7 ppts q-o-q increase in the NCC ratio in 1Q25 was primarily driven by the announcement of a US\$ 25 million increase to the buyback programme and related cash outflows for share repurchases, partially offset by a 10.8% growth in total portfolio value.
- On a y-o-y basis, the NCC ratio improved by 1.3 ppts, notwithstanding the substantial cash outflow for GCAP's share buyback and cancellation programmes.

US\$ Million	31-Mar-24	Change (y-o-y)	31-Dec-24	Change (q-o-q)	31-Mar-25
Cash and liquid funds	25.7	NMF	99.1	-41.0%	58.5
Loans issued	3.5	NMF	-	NMF	-
Gross debt	(150.7)	0.1%	(154.1)	-2.1%	(150.9)
Net debt (1)	(121.4)	-23.9%	(55.0)	+68.0%	(92.4)
Guarantees issued (2)	-	NMF	-	NMF	-
Net debt and guarantees issued (3)=(1)+(2)	(121.4)	-23.9%	(55.0)	+68.0%	(92.4)
Planned investments (4)	(46.5)	-18.1%	(42.2)	-9.7%	(38.1)
of which, planned investments in Renewable Energy	(28.9)	-19.7%	(24.8)	-6.5%	(23.2)
of which, planned investments in Education	(17.7)	-15.3%	(17.4)	-13.8%	(15.0)
Announced Buybacks (5)	-	NMF	(24.0)	-15.0%	(20.4)
Contingency/liquidity buffer (6)	(50.0)	NMF	(50.0)	NMF	(50.0)
Total planned investments, announced buybacks and contingency/liquidity buffer (7)=(4)+(5)+(6)	(96.5)	12.4%	(116.2)	-6.6%	(108.5)
Net capital commitment (3)+(7)	(218.0)	-7.8%	(171.3)	+17.3%	(200.9)
Portfolio value	1,473.2	+0.8%	1,340.1	+10.8%	1,485.4
NCC ratio	14.8%	-1.3 ppts	12.8%	+0.7 ppts	13.5%


NCC RATIO DEVELOPMENT OVERVIEW



NCC REPRESENTS AN AGGREGATED VIEW OF ALL CONFIRMED, AGREED AND EXPECTED CAPITAL OUTFLOWS AT THE GCAP HOLDCO LEVEL

We are targeting to reduce the balance of "net debt and guarantees issued" close to zero over the medium-term

NCC AND NCC RATIO DEVELOPMENT OVERVIEW¹



01 KEY DEVELOPMENTS IN 1Q25

NAV PER SHARE OVERVIEW AGGREGATED PORTFOLIO RESULTS OVERVIEW UPDATE ON DELEVERAGING NAV DISCOUNT DEVELOPMENT OVERVIEW

- **02** MACROECONOMIC UPDATE | GEORGIA
- **1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW**
- **04** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX




17

NAV PER SHARE DISCOUNT DEVELOPMENT OVERVIEW



DESPITE STRONG RECENT TRADING PERFORMANCE, THE DISCOUNT TO NAV PER SHARE REMAINS WIDE, PRESENTING AN ATTRACTIVE BUYING OPPORTUNITY




NAV PER SHARE DECOMPOSITION AS AT 6 MAY 2025¹



THE CURRENT SHARE PRICE LARGELY REFLECTS OUR LISTED AND OBSERVABLE PORTFOLIO, WHILE THE VALUE OF OUR PRIVATE ASSETS REMAINS MOSTLY OVERLOOKED

AS AT 6 MAY 2025	VALUE (GBP MILLION)	PER SHARE VALUE (GBP)
Listed and observable portfolio	591	16.5
Lion Finance Group	540	15.1
Water utility put option	51	1.4
Private portfolio	616	17.2
Of which, large portfolio companies	461	12.9
Of which, emerging and other portfolio companies	155	4.3
Total portfolio	1,208	33.8
Net debt	(74)	(2.1)
Total NAV	1,134	31.7



01 KEY DEVELOPMENTS IN 1Q25

02 MACROECONOMIC UPDATE | GEORGIA

1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW

04 LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX




20


GEORGIA'S ECONOMY IS ON AN UPWARD TRAJECTORY, WITH NOMINAL GDP PROJECTED TO EXCEED GEL 100 BILLION IN 2025




NOMINAL GDP IS EXPECTED TO EXCEED GEL 100 BILLION IN 2025



GDP GROWTH DECOMPOSITION BY SECTORS IN 2023-2024



GEORGIA'S ECONOMY CONTINUED TO EXPAND IN 2025, WITH PRELIMINARY ECONOMIC GROWTH AT 9.3% Y-O-Y IN 1Q25



** Preliminary estimate

GEORGIA CONTINUES TO BE ONE OF THE FASTEST GROWING ECONOMY IN OUR REGION | IMF (APRIL 2025)


Projected real GDP growth rates, % | IMF




STRONGER-THAN-EXPECTED ECONOMIC GROWTH IS SUPPORTED BY ROBUST DOMESTIC ACTIVITY AND EXTERNAL INFLOWS



LOANS GROWTH DECOMPOSITION BY PURPOSE (ON A CONSTANT CURRENCY BASIS)




THE UNEMPLOYMENT RATE FELL TO A RECORD LOW IN 2024, DRIVEN BY STRONG ECONOMIC PERFORMANCE



GENERAL GOVERNMENT FISCAL EXPENSES AND FISCAL DEFICIT (IMF MODIFIED)




FX INFLOWS REBOUNDED IN RECENT QUARTERS DRIVEN BY THE BASE EFFECT




PRICE PRESSURES HAVE RE-EMERGED, PUSHING INFLATION ABOVE 3% TARGET FOR THE FIRST TIME SINCE MARCH 2023




INFLATION REACHED 3.5% Y-O-Y, EXCEEDING THE TARGET FOR THE FIRST TIME SINCE MARCH 2023




NET NBG INTERVENTIONS ON THE FX MARKET AND OFFICIAL RESERVE ASSETS



MIXED INFLATION HAS BEEN PICKING UP THE MOST AMONG THE INFLATION COMPONENTS




THE GEL HAS APPRECIATED BY 2.3% YTD, MAINLY DUE TO THE WEAKER DOLLAR STANCE GLOBALLY




STRONG GROWTH IN RECENT YEARS DRIVES SIGNIFICANT DELEVERAGING, BOOSTING RESILIENCE AND UNLOCKING INVESTMENT POTENTIAL



GOVERNMENT DEBT AS A PERCENT OF GDP AT ITS LOWEST SINCE 2014, ON THE BACK OF STRONG ECONOMIC GROWTH AND EXCHANGE RATE APPRECIATION




DUE TO THE STRONG ECONOMIC GROWTH, CREDIT-TO-GDP RATIO REMAINS BELOW ITS LONG-TERM TREND




s the deviation of Creatt-to-GDP ratio from its long-run trena.

INTERNATIONAL INVESTMENT POSITION (% OF GDP) IMPROVED SIGNIFICANTLY, WHILE CURRENT ACCOUNT NARROWED TO -4.4% OF GDP IN 2024



MORTGAGE LOANS AS A % OF GDP DECLINES, AMID SOLID ECONOMIC GROWTH



Georgia Capital PLC | Source: NBG, Geostat, MOF, GCAP Estimates



STRONG GDP GROWTH – PROJECTED NOMINAL GDP TO SURPASS GEL 100 BILLION IN 2025
INFLATION HAS EXCEEDED THE TARGET FOR THE FIRST TIME IN TWO YEARS
NBG RE-ENTERED THE FX MARKET WITH A US\$ 102 MILLION PURCHASE IN MARCH
SIGNIFICANT DELEVERAGING, BOOSTING RESILIENCE AND UNLOCKING INVESTMENT POTENTIAL

- 01 KEY DEVELOPMENTS IN 1Q25
- **02** MACROECONOMIC UPDATE | GEORGIA
- **03** 1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW
- **04** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP


06 ANNEX



26

PORTFOLIO VALUE AS OF 31-MAR-25






Georgia Capital PLC |

- In 1Q25, our private portfolio companies were valued internally by incorporating the portfolio companies' 1Q25 results, in line with International Private Equity Valuation ("IPEV") guidelines and methodology deployed at the end of 2024 by an independent valuation company, which conducts external valuation assessment of the retail (pharmacy), insurance, healthcare services, renewable energy and education businesses semi-annually.
 The valuation of Water Utility in 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the heading of Water Utility in 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the heading of Water Utility of 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the heading of Water Utility of 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the heading of Water Utility of 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the heading of Water Utility of 1Q25 reflects the application of Water Utility of 1Q25 reflects the applicatio
 - The valuation of Water Utility in 1Q25 reflects the application of the put option valuation to GCAP's 20% holding in the business.
 LTM EV/EBITDA multiples for Retail (Pharmacy) and Healthcare are presented including IFRS 16 as of 31-Mar-25.
 - ETM EV/EDTDA multiples for Retail (marriady) and Realticate are presented including IRXs to as of start 4. Excluding the acquisition of Ardi, the implied LTM P/E valuation multiple stood at 11.1x at 31-Mar-25.
 - Lion Finance Group PLC, formerly known as Bank of Georgia Group PLC.

PORTFOLIO VALUE DEVELOPMENT IN 1Q25



PORTFOLIO VALUE UP BY 9.3% Q-O-Q TO GEL 4.1 **BILLION IN 1Q25 PRIVATE PORTFOLIO VALUE CREATION IN 1025** VALUE CREATION PRIVATE PORTFOLIO **GEL** million Retail (pharmacy) 66.3 49.2 Healthcare services 20.0 Insurance (P&C & medical) Emerging and other businesses (40.0) Total 95.5




RETAIL (PHARMACY) BUSINESS OPERATING PERFORMANCE OVERVIEW






KEY DRIVERS


- The 2.8% same-store revenue growth, strong ramp-up of the pharmacy stores launched in late 2023, and increased demand for seasonal medicines due to higher flu activity led to a 4.4% y-o-y increase in the retail revenue in 1Q25.
- The wholesale revenues were up by 40.6% y-o-y 1Q25, reflecting higher revenues from state healthcare programmes.
- Gross profit margin improved by 2.9 ppts y-o-y to 32.3% in 1Q25, further supported by the positive outcome of renegotiated trading terms with key suppliers and overall shift in the sales mix towards higher-margin non-prescription medicines.
- Operating expenses were up 10.0% y-o-y in 1Q25, due to increased salary and marketing expenses, attributable to the business growth.



KEY OPERATING HIGHLIGHTS



EBITDA¹ DEVELOPMENT



RETAIL (PHARMACY) BUSINESS VALUATION OVERVIEW




VALUE DEVELOPMENT OVERVIEW | 1Q25

(GEL MILLION) Change q-o-q -7.0% 0.0% +9.3% +4.5% 46 1,067 1,021 783 (277) (7) Equity value Enterprise value Net change Enterprise value Net debt inc. Minority 31-Mar-25 31-Mar-25 financial leases 31-Dec-24 in EV interest


VALUATION HIGHLIGHTS¹

GEL million, unless noted otherwise	31-Mar-25	31-Dec-24	Change
Enterprise value	1,067.1	1,021.0	46.1
LTM EBITDA	130.1	121.0	9.1
Implied EV/EBITDA multiple	8.2x	8.4x	(0.2x)
Net debt inc. lease liabilities	(277.2)	(297.9)	20.8
Equity value of GCAP's share	783.0	716.1	66.9

IMPLIED LTM EV/EBITDA DEVELOPMENT



ADJUSTED NET DEBT TO EBITDA² (excl. IFRS 16)



Georgia Capital PLC | 1. In 1Q25, our private portfolio companies were valued internally by incorporating the portfolio companies' 1Q25 results, in line with International Private Equity Valuation ("IPEV") guidelines and methodology deployed at the end of 2024 by an independent valuation company. 2. Figures take into account the application of the minority buyout agreement.

30

INSURANCE BUSINESS OPERATING PERFORMANCE OVERVIEW






KEY DRIVERS

P&C Insurance

- The increase in the P&C insurance revenue is mainly driven by the growth in the motor and credit life insurance lines.
- The combined ratio for P&C insurance was up by 0.6 ppts y-o-y in 1Q25, mainly due to a few large property insurance claims during the quarter.

Medical Insurance

- The revenue of the medical insurance business reflects organic portfolio growth, a mid-teen percentage increase in insurance policy prices and the positive impact of the acquisition of Ardi insurance portfolio in April 2024.
- The combined ratio for medical insurance increased by 1.2 ppts y-o-y in 1Q25, reflecting a higher expense ratio on the back of an increase in salaries in line with the business expansion.



KEY OPERATING HIGHLIGHTS


P&C Insurance		1Q24	VS.	• 1Q25	<u>Change y-o-y</u>
Gross premium written (MGEL)	44.6				49.2 +10.3%
Combined ratio	87.1%				87.7% +0.6 ppts
Number of policies written	83,867				104,301 +24.4%
Medical Insurance					
Gross premium written (MGEL)	51.4				<u>89.2</u> + 73.3%
Combined ratio	97.2%				98.4% +1.2 ppts
Number of individuals insured	170,961				277,500 +62.3%

PRE-TAX PROFIT DEVELOPMENT



INSURANCE BUSINESS ÎN Ș **VALUATION OVERVIEW**


VALUE DEVELOPMENT OVERVIEW | 1Q25 (GEL MILLION)




VALUATION HIGHLIGHTS¹

GEL million, unless noted otherwise	31-Mar-25	31-Dec-24	Change
LTM pre-tax profit ²	39.7	38.6	1.1
Implied P/E multiple ³	9.8x	9.7x	0.1x
Equity value	441.1	427.9	13.1
LTM ROAE ⁴ – P&C Insurance	32.5%	33.3%	(0.8) ppts
LTM ROAE ⁴ – Medical Insurance	39.0%	37.6%	1.4 ppts

IMPLIED LTM P/E MULTIPLE DEVELOPMENT³



NET DEBT TO EBITDA



31-Mar-24 31-Dec-24 31-Mar-25 TARGET

Georgia Capital PLC | 1. In 1Q25, our private portfolio companies were valued internally by incorporating the portfolio companies' 1Q25 results, in line with International Private Equity Valuation ("IPEV") guidelines and methodology deployed at the end of 2024 by an independent valuation company. 2. Adjusted for non-recurring items. 3. Excluding the acquisition of Ardi, the implied LTM P/E valuation multiple remained unchanged q-o-q at 11.1x at 31-Mar-25. 4. Calculated based on average equity, adjusted for preferred shares.



HEALTHCARE SERVICES BUSINESS OPERATING PERFORMANCE OVERVIEW

GEL MILLION



23

18


1025

Hospitals



KEY DRIVERS

- A 19.2% y-o-y total revenue growth reflects:
 - increased demand for high revenue-generating outpatient services at our large and specialty hospitals;
 - optimisation of the facilities and significant improvement in sales mix at our regional and community hospitals; and
 - robust performance of the clinics and diagnostics business, driven by a growing customer base in alignment with enhanced service offerings.
- Operating expenses (excl. IFRS 16) were up by 9.0% y-o-y in 1Q25, primarily due to higher salary and rent expenses associated with the business expansion.



KEY OPERATING HIGHLIGHTS

Occupancy rates at hospitals:		1Q24	VS.	• 1Q25		<u>Change y-o-y</u>
of which, large and specialty hospitals	69.8%				73.8%	+4.0 ppts
of which, regional and community hospitals	81.5%				76.9%	-4.7 ppts
Number of admissions at hospitals ('000):						
of which, large and specialty hospitals	172.3				188.0	+9.1%
of which, regional and community hospitals	237.4				212.0	-10.7%
Clinics and diagnostics:						
Number of admissions at Clinics ('000)	461.4				503.4	+9.1%
Number of patients served at Diagnostics ('000)	221				230	+40%

HEALTHCARE BUSINESS VALUATION OVERVIEW

VALUE DEVELOPMENT OVERVIEW | 1Q25


(GEL MILLION)

Change q-o-q		+8.5%	+4.8%	+2.0%	+12.0%
779	66	845			
			(349)	(33)	463
Enterprise value 31-Dec-24	Net change in EV	Enterprise value 31-Mar-25	Net debt inc. financial leases	Minority interest	Equity value 31-Mar-25


VALUATION HIGHLIGHTS¹

GEL million, unless noted otherwise	31-Mar-25	31-Dec-24	Change
Enterprise value	844.7	778.6	66.1
LTM EBITDA	82.1	74.2	7.9
Implied EV/EBITDA multiple	10.3x	10.5x	(0.2x)
Net debt inc. lease liabilities	(348.7)	(332.7)	(16.0)
Equity value of GCAP's share	463.3	413.9	49.5

IMPLIED LTM EV/EBITDA DEVELOPMENT



NET DEBT TO EBITDA (excl. IFRS 16)



Georgia Capital PLC | 1. In 1Q25, our private portfolio companies were valued internally by incorporating the portfolio companies' 1Q25 results, in line with International Private Equity Valuation ("IPEV") guidelines and methodology deployed at the end of 2024 by an independent valuation company.



GEORGIA

- 01 KEY DEVELOPMENTS IN 1Q25
- **02** MACROECONOMIC UPDATE | GEORGIA
- **1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW**


05 WRAP-UP

06 ANNEX



LIQUIDITY OUTLOOK

LIQUIDITY DEVELOPMENT OVERVIEW (US\$ MILLION)





LIQUIDITY DOWN BY 41.0% IN 1Q25, MAINLY REFLECTING SHARE BUYBACKS DURING THE QUARTER

DIVIDEND INCOME OUTLOOK

4.3 +11.6% **Dividend** income 1.6 2.1 4.1 per share (GEL) 180¹ 179¹ 180+ **GEL MILLION** 57 94 44 OUTLOOK 50 172 74 73 60 30 81 72 41 30 29 1**Q**25 15 2019 2020 2021 2022 2023 2024 2025 Dividend income from listed companies Buyback dividend Dividend income from private companies

RECURRING CASH DIVIDEND INCOME FROM PORTFOLIO COMPANIES

Georgia Capital PLC | 1. In 2023 and 2024, GCAP received one-off non-recurring inflows of GEL 56.1 million and GEL 22.6 million, respectively. 2. The 1Q25 dividend income per share assumes the collection of GEL 180 million dividends in line with the 2025 outlook, and takes into account the number of issued shares as of 6-May-25.



GEL 8.0 MILLION RECURRING DIVIDEND INCOME IN 1Q25

DIVIDEND INCOME	(GEL million)		
nsurance business	7.0		
of which, P&C insurance	5.8		
of which, medical insurance	1.2		
luto service	1.0		
TOTAL	8.0		

SOLID DIVIDEND INCOME OUTLOOK IN 2025

180+ GEL MILLION

- 01 KEY DEVELOPMENTS IN 1Q25
- **02** MACROECONOMIC UPDATE | GEORGIA
- **1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW**
- **04** LIQUIDITY AND DIVIDEND INCOME OUTLOOK

05 WRAP-UP

06 ANNEX



SOLID PERFORMANCE ACROSS OUR PORTFOLIO



PERFORMANCE HIGHLIGHTS

✓	NAV per share (GEL) increased 11.2% in 1Q25, driven by continued growth in Lion Finance Group's share price and the robust operating performance of the private portfolio companies
✓	Outstanding quarterly results across our large private portfolio companies with 21.2% and 45.8% y-o-y increases in aggregated revenues and EBITDA in 1Q25, respectively, leading to a 25.2% y-o-y increase in net operating cash flow
✓	NCC ratio increased by 0.7 ppts q-o-q to 13.5% as at 31-Mar-25, mainly reflecting the announcement of a US\$ 25 million increase to the buyback programme in March 2025
✓	2.1 million shares repurchased since the beginning of 2025 (total bought back since demerger now 13.2 million shares (US\$ 164 million cost), representing 27.6% of GCAP's peak issued share capital)

OUTLOOK

€	Significant value creation potential, supported by our robust capital return programme
€	Substantial progress on deleveraging
€	Strong economic growth outlook

- 01 KEY DEVELOPMENTS IN 1Q25
- **02** MACROECONOMIC UPDATE | GEORGIA
- **1Q25 PORTFOLIO RESULTS AND VALUATIONS OVERVIEW**
- **04** LIQUIDITY AND DIVIDEND INCOME OUTLOOK
- 05 WRAP-UP

06 ANNEX



VALUATION PEER GROUP











- NEUCA S.A. | Poland
- Sopharma Trading AD | Bulgaria
- S.C. Ropharma S.A. | Romania
- SALUS, Ljubljana, d. d. | Slovenia
- Great Tree Pharmacy Co., Ltd. | Taiwan
- Dis-Chem Pharmacies Limited | South Africa
- Clicks Group Limited | South Africa

- Dhipaya Insurance | Thailand
- Zavarovalnica Triglav | Slovenia
- Pozavarovalnica Sava | Slovenia
- Aksigorta | Turkey
- Anadolu Sigorta | Turkey
- Bao Minh Insurance | Vietnam
- Turkiye Sigorta | Turkey

 Powszechny Zaklad Ubezpieczen SA | Poland

MEDICAL

INSURANCE

- Allianz SE | Germany
- UNIQA Insurance Group AG | Austria
- Ageas SA/NV | Belgium



- Medicover AB | Sweden
- EMC Instytut Medyczny SAEMC SA | Poland
- Med Life S.A. | Romania
- Netcare Limited | South Africa
- MLP Saglik Hizmetleri A.S. | Turkey
- Life Healthcare Group Holdings Limited | South Africa
- Fleury S.A. | Brazil

PRIVATE PORTFOLIO COMPANIES' DEBT MATURITY PROFILE



GROSS DEBT MATURITY AS OF 31 MARCH 2025 (GEL MILLION)	2025	2026	2027	2028 - 2036	Total
Large portfolio companies	150.2	135.5	110.2	169.2	565.1
Retail (pharmacy)	79.0	38.3	29.7	22.7	169.7
Insurance (P&C and medical)	3.0	6.5	7.3	12.7	29.5
Healthcare services	68.2	90.7	73.1	133.8	365.8
Emerging and other portfolio companies	56.0	110.8	220.5	65.8	453.0
Total	206.2	246.3	330.7	235.0	1,018.1

FORWARD LOOKING STATEMENTS



This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, eretain of which are beyond our control, include, among other things: regional instability; regional instability; currency fluctuations and risk, including depreciation of the Georgian Lari, and macroeconomic risk, regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; and other key factors that could diversely affect our business and financial performance, including those which are contained elsewhere in this presentation and in our past and future filings and reports and also the 'Principal Risks and Uncertainties' included in Georgia Capital PLC's Annual Report and Accounts 2024. No part of this presentation constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-